Login / Signup

Implication of myeloid differentiation factor 88 inhibitor TJ-M2010-5 for therapeutic intervention of hepatocellular carcinoma.

Jing LiuXue ZhangHaizhou WangMeng ZhangYanan PengMingqiang LiLin XieFengchao JiangYiping GongQiu ZhaoPing Zhou
Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2019)
These results indicate that MyD88 is a feasible target for antitumor treatment and TJ-M2010-5 is a qualified candidate for HCC therapy.
Keyphrases
  • randomized controlled trial
  • bone marrow
  • acute myeloid leukemia
  • stem cells
  • immune response